Payment overview · 2025
General Payments
$672.70
39 reported records · 14 companies
Healthcare provider profile · identity verified
Stephanie Renee Roach, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · KINGSPORT, TN · NPI 1275820599
Verified facts
What the public records show
CMS Open Payments records show Stephanie Renee Roach, FNP received $672.70 in general payments during 2025 across 39 reported records.
Abbott Laboratories accounted for 24.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 163 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $162.68 | 24.2% | 12 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $150.77 | 22.4% | 9 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $69.97 | 10.4% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $59.13 | 8.8% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $34.45 | 5.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $30.67 | 4.6% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $23.81 | 3.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $23.55 | 3.5% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $22.24 | 3.3% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.00 | 3.1% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $20.51 | 3.0% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $20.30 | 3.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.98 | 2.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.64 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $672.70 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $162.68 | 12 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $91.20 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $69.97 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $59.13 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $45.77 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $45.32 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $34.45 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $30.67 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $23.81 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $23.55 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $22.24 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $22.24 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $21.00 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $20.51 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $20.30 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $18.98 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $16.81 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $14.64 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $13.86 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $13.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 163 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 58 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 94 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
56 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
58 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
112 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
94 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
163 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 637 | 131 |
| Gabapentin | Gabapentin | 578 | 113 |
| Omeprazole | Omeprazole | 574 | 124 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 562 | 84 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 490 | 121 |
| Oxycodone Hcl | Oxycodone Hcl | 423 | 50 |
| Montelukast Sodium | Montelukast Sodium | 391 | 94 |
| Furosemide | Furosemide | 315 | 76 |
| Pantoprazole Sodium | Pantoprazole Sodium | 285 | 69 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 282 | 79 |
| Lisinopril | Lisinopril | 273 | 75 |
| Alprazolam | Alprazolam | 260 | 31 |
| Losartan Potassium | Losartan Potassium | 246 | 70 |
| Amlodipine Besylate | Amlodipine Besylate | 240 | 64 |
| Trazodone Hcl | Trazodone Hcl | 237 | 42 |
| Famotidine | Famotidine | 224 | 59 |
| Baclofen | Baclofen | 203 | 44 |
| Metoprolol Succinate | Metoprolol Succinate | 203 | 53 |
| Quetiapine Fumarate | Quetiapine Fumarate | 203 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 202 | 52 |
| Atorvastatin Calcium | Atorvastatin Calcium | 196 | 53 |
| Meloxicam | Meloxicam | 196 | 44 |
| Fluticasone Propionate | Fluticasone Propionate | 194 | 63 |
| Duloxetine Hcl | Duloxetine Hcl | 187 | 49 |
| Metformin Hcl | Metformin Hcl | 184 | 42 |
| Potassium Chloride | Potassium Chloride | 182 | 48 |
| Tizanidine Hcl | Tizanidine Hcl | 179 | 44 |
| Allopurinol | Allopurinol | 171 | 41 |
| Clopidogrel | Clopidogrel Bisulfate | 170 | 40 |
| Tramadol Hcl | Tramadol Hcl | 170 | 41 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 169 | 40 |
| Metformin Hcl Er | Metformin Hcl | 166 | 52 |
| Eliquis | Apixaban | 163 | 28 |
| Ondansetron Odt | Ondansetron | 159 | 57 |
| Pravastatin Sodium | Pravastatin Sodium | 156 | 41 |
| Zolpidem Tartrate | Zolpidem Tartrate | 148 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 147 | 38 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 146 | 29 |
| Buspirone Hcl | Buspirone Hcl | 138 | 32 |
| Torsemide | Torsemide | 138 | 38 |
| Glipizide Er | Glipizide | 135 | 39 |
| Lorazepam | Lorazepam | 130 | 18 |
| Azithromycin | Azithromycin | 129 | 111 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 129 | 40 |
| Simvastatin | Simvastatin | 128 | 29 |
| Sucralfate | Sucralfate | 125 | 42 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 124 | 24 |
| Atenolol | Atenolol | 123 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 122 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 122 | 28 |
| Nitroglycerin | Nitroglycerin | 117 | 40 |
| Pregabalin | Pregabalin | 116 | 26 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 115 | 29 |
| Carvedilol | Carvedilol | 113 | 21 |
| Symbicort | Budesonide/Formoterol Fumarate | 112 | 22 |
| Sertraline Hcl | Sertraline Hcl | 108 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 107 | 32 |
| Ezetimibe | Ezetimibe | 105 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 104 | 25 |
| Clonazepam | Clonazepam | 103 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 103 | 31 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 98 | 18 |
| Propranolol Hcl | Propranolol Hcl | 97 | 21 |
| Ozempic | Semaglutide | 94 | 20 |
| Diazepam | Diazepam | 86 | 15 |
| Ibuprofen | Ibuprofen | 86 | 21 |
| Methylprednisolone | Methylprednisolone | 84 | 76 |
| Alendronate Sodium | Alendronate Sodium | 82 | 23 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 81 | 27 |
| Cephalexin | Cephalexin | 79 | 59 |
| Clonidine Hcl | Clonidine Hcl | 79 | 23 |
| Nystatin | Nystatin | 78 | 25 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 77 | 68 |
| Mounjaro | Tirzepatide | 77 | 14 |
| Spironolactone | Spironolactone | 77 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 76 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 75 | 15 |
| Trulicity | Dulaglutide | 74 | 14 |
| Mirtazapine | Mirtazapine | 73 | 22 |
| Topiramate | Topiramate | 71 | 17 |
| Fluconazole | Fluconazole | 70 | 49 |
| Testosterone Cypionate | Testosterone Cypionate | 69 | 12 |
| Glipizide | Glipizide | 68 | 21 |
| Finasteride | Finasteride | 66 | 17 |
| Promethazine Hcl | Promethazine Hcl | 66 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 62 | 56 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 61 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 61 | 15 |
| Farxiga | Dapagliflozin Propanediol | 58 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 58 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 56 | 47 |
| Linzess | Linaclotide | 56 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 56 | 39 |
| Chlorthalidone | Chlorthalidone | 55 | 17 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 55 | 17 |
| Prednisone | Prednisone | 55 | 33 |
| Donepezil Hcl | Donepezil Hcl | 54 | 11 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 52 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 52 | 11 |
| Temazepam | Temazepam | 50 | suppressed |
| Methocarbamol | Methocarbamol | 49 | suppressed |
| Synthroid | Levothyroxine Sodium | 48 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 46 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 46 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | 13 |
| Methimazole | Methimazole | 45 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 43 | 13 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 43 | suppressed |
| Fenofibrate | Fenofibrate | 42 | 12 |
| Meclizine Hcl | Meclizine Hcl | 42 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 41 | 12 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 40 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 40 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 39 | suppressed |
| Jardiance | Empagliflozin | 39 | suppressed |
| Estradiol | Estradiol | 36 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 35 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Levofloxacin | Levofloxacin | 35 | 30 |
| Celecoxib | Celecoxib | 34 | suppressed |
| Olanzapine | Olanzapine | 34 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 34 | suppressed |
| Lovastatin | Lovastatin | 32 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 32 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 31 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 30 | 11 |
| Morphine Sulfate Er | Morphine Sulfate | 30 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 29 | suppressed |
| Xtampza Er | Oxycodone Myristate | 29 | suppressed |
| Amoxicillin | Amoxicillin | 28 | 20 |
| Clindamycin Hcl | Clindamycin Hcl | 28 | 24 |
| Naproxen | Naproxen | 28 | suppressed |
| Nyamyc | Nystatin | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 27 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Colchicine | Colchicine | 26 | 11 |
| Lansoprazole | Lansoprazole | 26 | suppressed |
| Pentoxifylline | Pentoxifylline | 26 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Armour Thyroid | Thyroid,pork | 25 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | suppressed |
| Cilostazol | Cilostazol | 23 | suppressed |
| Ibu | Ibuprofen | 23 | suppressed |
| Lamotrigine | Lamotrigine | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 22 | suppressed |
| Metolazone | Metolazone | 22 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 22 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 18 |
| Belsomra | Suvorexant | 20 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 20 | 18 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 17 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 17 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 17 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Alprazolam Er | Alprazolam | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 13 | suppressed |
| Oxazepam | Oxazepam | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $672.70 · 39 records | Abbott Laboratories | AIRSUPRA, ARISTADA, Auvelity, BREZTRI, CAPLYTA, Cologuard Collection Kit, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, INSPIRE, Kerendia, LYBALVI, NURTEC ODT, Ozempic, REXULTI, Rybelsus, UBRELVY, Veozah, YUPELRI, ZAVZPRET | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error